Bioheart(02185.HK): Bioheart® Bioresorbable Drug-Eluting Stent Granted Registration Approval by NMPA

NewTimeSpace · 2026/07/02 07:24 · By Xuran Lin

NewTimeSpace News: In a voluntary announcement dated July 2, Bioheart disclosed that Bioheart® bioresorbable drug-eluting stent independently developed by the Company has obtained registration approval from the National Medical Products Administration (NMPA), indicated for the treatment of patients with ischaemic heart disease caused by de novo coronary artery lesions.

NewTimeSpace News: On July 2, 2026, Bioheart(02185.HK) issued a voluntary announcement, stating that Bioheart® bioresorbable drug-eluting stent (BRS), independently researched and developed by the Company, has been approved for registration by the National Medical Products Administration (NMPA).

This product is intended to treat patients suffering from ischaemic heart disease arising from de novo coronary artery lesions, so as to improve the luminal diameter of coronary arteries. The Company cautions that there is no guarantee for the successful final development and commercialization of this product, and investors shall exercise prudence when trading the Company’s shares.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.

Tags：

Bioheart 02185.HK